Scleritis
13
1
1
6
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
23.1%
3 terminated out of 13 trials
66.7%
-19.8% vs benchmark
8%
1 trials in Phase 3/4
100%
6 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (13)
AutoInflammatory Disease Alliance Registry (AIDA)
A Clinical Study to Evaluate the Potential Role of ACTH Gel in Patients With Scleritis
LSFG-SKIN, Laser Speckle Flowgraphy
Human Samples and Data Repository
Ocular Manifestations in Rheumatic Diseases
Tofacitinib for Inflammatory Eye Disease
Sirolimus Injections for Autoimmune Scleritis
Gevokizumab for Active Scleritis
Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients
Infliximab to Treat Non-Infectious Scleritis
Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation
Causes of Visual Loss in Retinal Disease
Study Evaluating PSI-697 in Patients With Scleritis